Ovarian hyperstimulation syndrome associated with the use of the gonadotropin-releasing hormone agonist leuprolide acetate.
Severe ovarian hyperstimulation syndrome occurred after the administration of LA to suppress multicystic ovaries. It is possible that this patient with multiple ovarian cysts, each 2 to 3 cm in size, is at increased risk for a paradoxical stimulatory rather than inhibitory response to GnRH-a.
Droesch
K
K
Department of Obstetrics and Gynecology, State University of New York at Stony Brook 11794-8091.
Barbieri
R L
RL
D000328:Adult; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects*; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced* / Q000188:drug therapy; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy; D013738:Testolactone / Q000627:therapeutic use
D004958:Estradiol; D013738:Testolactone; D016729:Leuprolide